Dual Targeting of GPRC5D and BCMA Gets High Response Rate in Extramedullary Myeloma

(MedPage Today) — ORLANDO — For triple-class exposed relapsed or refractory multiple myeloma with extramedullary disease (EMD), a combination of talquetamab (Talvey) and teclistamab (Tecvayli) achieved high response rates in updated results…

Source link : https://www.medpagetoday.com/meetingcoverage/ashhematology/118891

Author :

Publish date : 2025-12-08 19:32:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Dual Targeting of GPRC5D and BCMA Gets High Response Rate in Extramedullary Myeloma

Odd elements in supernova blast might have implications for alien life

Trial Results Could Shuffle Order of BTK Inhibitors for CLL/SLL

Related Posts

Gun Injuries in Parents Linked to Mental Health Issues in Kids

Psoriatic Disease: QOL Improved With GLP-1 RA Plus Biologic

New Stroke Guideline Pushes EVT for Larger Core Strokes, Mobile Stroke Units

Nearly Half of Americans Expected to Have Obesity in the Next 10 Years

A Call to Consider Patients’ Medication List When Prescribing Cancer Immunotherapy

How to Survive Night Shifts as a Resident

Gun Injuries in Parents Linked to Mental Health Issues in Kids

Psoriatic Disease: QOL Improved With GLP-1 RA Plus Biologic

New Stroke Guideline Pushes EVT for Larger Core Strokes, Mobile Stroke Units

Nearly Half of Americans Expected to Have Obesity in the Next 10 Years

A Call to Consider Patients’ Medication List When Prescribing Cancer Immunotherapy

How to Survive Night Shifts as a Resident

Next DSM Insights; FDA Reviewing Non-Stimulant ADHD Drug; 10M People Microdosing

Viral and Nonviral NICU Infection Rates Diverged During the COVID Pandemic

Categories

Archives